Efficacy of Dual Hormonal Therapy with Fulvestrant and Aromatase Inhibitors as Neoadjuvant Endocrine Treatment for Locally Advanced Breast Cancer
- PMID: 40647384
- PMCID: PMC12248958
- DOI: 10.3390/cancers17132083
Efficacy of Dual Hormonal Therapy with Fulvestrant and Aromatase Inhibitors as Neoadjuvant Endocrine Treatment for Locally Advanced Breast Cancer
Abstract
Background: The role of neoadjuvant endocrine therapy (NET) in patients with luminal tumors is still not well defined in everyday clinical practice. To assess the efficacy of combination NET, we analyzed the outcomes of fulvestrant and aromatase inhibitors (AI) in combination in a real-world population. Methods: This was a single-arm, retrospective longitudinal study of the total population of patients diagnosed with locoregionally advanced, clinical stage II-III, HR+ HER2-, luminal-type eBC, who were treated with the neoadjuvant combination of fulvestrant and AI between 2019 and 2024 at the Clinical University Hospital of Split, Croatia. Results: We enrolled 44 patients in the intention-to-treat (ITT) population, while 34 completed NET and surgery (per-protocol population; PPP). The median duration of NET was 11 months (interquartile range [IQR] of 9-16 months). The best radiological objective response rate (partial or complete response) was achieved by 30 (68.2%) in ITT, and 26 (76.5%) in PPP, defined by radiological examination, breast ultrasound, or MR. In the PPP, the minimal or moderate pathological response according to residual cancer burden (I or II) was observed in 29 (85.3%) patients. The median of absolute changes in Ki-67 was -5 (95% CI: -9 to 0), and the median of relative Ki67 changes was -40% (95% CI: -72% to 0%). Post-surgical Ki-67 was significantly predicted by initial Ki-67, positive lymph nodes, and time from diagnosis to the initiation of NET. Treatment was well tolerated, with no therapy discontinuation or dose reductions needed due to toxicity. The most commonly reported side effects included musculoskeletal pain (45.5%), asthenia (34.1%), and hot flashes (29.5%). Conclusions: Dual hormonal therapy with fulvestrant and AI is an active, easily given, non-toxic, promising neoadjuvant treatment in real-world patients with locally advanced luminal-type eBC who are not candidates for chemotherapy.
Keywords: Ki-67 antigen; aromatase inhibitors; breast neoplasms; endocrine therapy; fulvestrant; neoadjuvant therapy; real-world evidence.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.JAMA Oncol. 2024 Mar 1;10(3):362-371. doi: 10.1001/jamaoncol.2023.6038. JAMA Oncol. 2024. PMID: 38236590 Free PMC article. Clinical Trial.
-
Fulvestrant for hormone-sensitive metastatic breast cancer.Cochrane Database Syst Rev. 2017 Jan 3;1(1):CD011093. doi: 10.1002/14651858.CD011093.pub2. Cochrane Database Syst Rev. 2017. PMID: 28043088 Free PMC article.
-
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.Cochrane Database Syst Rev. 2015 Apr 7;(4):CD010260. doi: 10.1002/14651858.CD010260.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2022 Aug 22;8:CD010260. doi: 10.1002/14651858.CD010260.pub3. PMID: 25847525 Updated.
-
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003370. doi: 10.1002/14651858.CD003370.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2009 Oct 07;(4):CD003370. doi: 10.1002/14651858.CD003370.pub3. PMID: 17253488 Updated.
-
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2. Cochrane Database Syst Rev. 2020. PMID: 33075160 Free PMC article.
References
-
- Croatian Institute of Public Health Incidence of Cancer in Croatia 2022. [(accessed on 5 June 2025)]. Available online: https://www.hzjz.hr/periodicne-publikacije/incidencija-raka-u-hrvatskoj-...
-
- Rastogi P., Anderson S.J., Bear H.D., Geyer C.E., Kahlenberg M.S., Robidoux A., Margolese R.G., Hoehn J.L., Vogel V.G., Dakhil S.R., et al. Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J. Clin. Oncol. 2008;26:778–785. doi: 10.1200/JCO.2007.15.0235. - DOI - PubMed
-
- Loibl S., Jackisch C., Schneeweiss A., Schmatloch S., Aktas B., Denkert C., Wiebringhaus H., Kümmel S., Warm M., Paepke S., et al. Dual HER2-Blockade with Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer: A Subanalysis of Data from the Randomized Phase III GeparSepto Trial. Ann. Oncol. 2017;28:497–504. doi: 10.1093/annonc/mdw610. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous